During the last session, Intellia Therapeutics Inc (NASDAQ:NTLA)’s traded shares were 4.15 million, with the beta value of the company hitting 2.16. At the end of the trading day, the stock’s price was $8.31, reflecting an intraday loss of -4.81% or -$0.42. The 52-week high for the NTLA share is $28.23, that puts it down -239.71 from that peak though still a striking 0.12% gain since the share price plummeted to a 52-week low of $8.30. The company’s market capitalization is $860.23M, and the average intraday trading volume over the past 10 days was 2.83 million shares, and the average trade volume was 3.21 million shares over the past three months.
Intellia Therapeutics Inc (NTLA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.71. NTLA has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 13 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.26.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Intellia Therapeutics Inc (NTLA) registered a -4.81% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.81% in intraday trading to $8.31, hitting a weekly high. The stock’s 5-day price performance is -10.65%, and it has moved by -22.41% in 30 days. Based on these gigs, the overall price performance for the year is -69.12%. The short interest in Intellia Therapeutics Inc (NASDAQ:NTLA) is 26.69 million shares and it means that shorts have 7.06 day(s) to cover.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 62.23% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $60 respectively. As a result, NTLA is trading at a discount of -622.02% off the target high and -8.3% off the low.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
In the rating firms’ projections, revenue will decrease -17.91% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 11.39M as predicted by 20 analyst(s). Meanwhile, a consensus of 20 analyst(s) estimates revenue growth to 11.37M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 28.93M and 6.96M respectively. In this case, analysts expect current quarter sales to shrink by -60.65% and then jump by 63.41% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -20.04%. While earnings are projected to return 11.04% in 2025, the next five years will return 25.47% per annum.
NTLA Dividends
Intellia Therapeutics Inc is due to release its next quarterly earnings on 2025-Feb-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Intellia Therapeutics Inc insiders own 5.05% of total outstanding shares while institutional holders control 91.72%, with the float percentage being 96.60%. ARK INVESTMENT MANAGEMENT LLC is the largest shareholder of the company, while 417.0 institutions own stock in it. As of 2024-06-30, the company held over 11.6 million shares (or 11.9575% of all shares), a total value of $259.51 million in shares.
The next largest institutional holding, with 9.6 million shares, is of BLACKROCK INC.’s that is approximately 9.897% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $214.79 million.
Also, the Mutual Funds coming in first place with the largest holdings of Intellia Therapeutics Inc (NTLA) shares are ARK Innovation ETF and ARK Genomic Revolution ETF . Data provided on Feb 28, 2025 indicates that ARK Innovation ETF owns about 8.72 shares. This amounts to just over 8.42 percent of the company’s overall shares, with a $72.45 million market value. The same data shows that the other fund manager holds slightly less at 3.09, or about 2.98% of the stock, which is worth about $25.64 million.
